Stock

Falling IPO Stocks Analysts Still Rate a Buy

109 IPO stocks have fallen over three months while the analyst consensus and our own score both stayed positive. The full screen, with the numbers.

This screen looks for one thing: a share price that has fallen over three months while both the analyst consensus and our own score stayed positive. It is a disagreement, not a verdict. Either the market has seen something the published views have not caught up with, or the views are right and the price overshot. The screen cannot tell you which — it tells you where to look, and shows the numbers that make each case.

Data as of 2026-11-09. 109 of 470 tracked IPOs qualify. Sorted by the three-month change, biggest fall first. The companion screen, where the price rose while the rating stayed cautious, runs the same test in the other direction.

Price fell, rating held

Flags
what we computewhat you can get elsewhere too
TickerCompanyOur balanceFundamentalsFlagsIPOMarket capLast3-monthSince IPOAnalyst indexConsensusTarget
WYFIWhiteFiber, Inc.Leans up +2
medium
loss-making -132.2%
revenue +66.2%
heavily indebted
Fell on sound metrics, Large daily move, Halved from offer2025-08-07$427M$7.65-68.9%-42.2%8.2Strong Buy (11)$31.45 +311%
UMACUnusual Machines, Inc.Leans up +2
medium
loss-making -75.9%
revenue +101.2%
—2024-02-14$586M$10.15-62.6%+238.2%8.3Strong Buy (9)$30.11 +197%
BLZEBackblaze, Inc.Leans up +2
weak
loss-making -11.5%
revenue +14.3%
heavily indebted
Fell, analysts held, Improving confidence, Large daily move, Halved from offer2021-11-11$489M$7.27-60.1%-56.7%7.1Buy (7)$21.50 +196%
BCAXBicara Therapeutics Inc.Leans up +2
weak
—Fell, analysts held, Monthly spike, Halved from offer2024-09-13$665M$9.12-59.8%-49.0%7.5Buy (14)$32.17 +253%
IRENIREN LimitedUp +4
strong
loss-making -194.4%
revenue +41.1%
heavily indebted
Fell on sound metrics, Improving confidence, Monthly spike2021-11-17$7.7B$14.41-59.5%-34.0%7.0Buy (20)$56.69 +293%
ITGITG, Inc.Up +4
strong
profitable 1.1%
revenue +15.7%
heavily indebted
Fell on sound metrics, Profitable but deeply down, Large daily move, Weekly spike, Halved from offer2026-07-01$705M$6.18-54.2%-52.6%9.4Strong Buy (9)$11.33 +83%
CRDOCredo Technology Group Holding LtdLeans up +3
medium
profitable 33.8%
revenue +205.7%
—2022-01-27$24.7B$117.76-53.5%+2.1%8.3Strong Buy (20)$277.47 +136%
EROCERock, Inc.Up +4
strong
loss-making -50.2%
revenue +42.5%
heavily indebted
Fell on sound metrics, Halved from offer2026-06-10$2.3B$7.25-51.7%-56.6%7.5Buy (8)$18.88 +160%
CADLCandel Therapeutics, Inc.Leans up +2
weak
heavily indebted
Fell, analysts held, Improving confidence, Large daily move, Weekly spike2021-07-27$486M$5.13-49.0%-28.1%10.0Strong Buy (10)$17.67 +244%
INIOInnio N.V.Leans up +3
medium
profitable 2.7%
revenue +22.1%
heavily indebted
Lock-up expiry, Fell on sound metrics, Halved from offer2026-06-04$10.9B$12.81-48.2%-35.7%6.0Buy (10)$31.40 +145%
APMDApnimed, Inc.Leans up +2
weak
profitable 83.8%
revenue +380.1%
—2026-07-31$704M$17.25-48.0%+7.8%10.0Strong Buy (4)$50.33 +192%
QNTQuantinuum Inc.Leans up +3
medium
loss-making -106.4%
revenue +34.6%
heavily indebted
Lock-up expiry, Fell on sound metrics2026-06-04$9.4B$27.96-46.4%-51.4%8.9Strong Buy (14)$71.15 +154%
RAPPRapport Therapeutics, Inc.Leans up +2
weak
pre-revenue
heavily indebted
—2024-06-07$1.6B$23.59-46.0%+58.2%9.7Strong Buy (16)$64.21 +172%
NNENANO Nuclear Energy Inc.Leans up +3
weak
pre-revenue
—2024-05-08$597M$9.97-43.3%+174.0%7.2Buy (9)$34.75 +249%
CLYMClimb Bio, Inc.Leans up +3
weak
——2021-08-10$609M$9.28-40.6%-21.6%9.4Strong Buy (16)$28.40 +206%
AURAurora Innovation, Inc.Leans up +2
medium
pre-revenue
revenue +200.0%
heavily indebted
Halved from offer2021-05-06$8.5B$3.84-39.6%—5.4Buy (13)$11.55 +201%
GLUEMonte Rosa Therapeutics, Inc.Up +4
strong
loss-making -186.2%
revenue +63.5%
heavily indebted
Fell on sound metrics, Halved from offer2021-06-24$801M$8.91-39.1%-50.4%9.0Strong Buy (10)$25.38 +185%
AVEXAEVEX Corp.Leans up +2
weak
loss-making -2.8%
revenue +10.4%
Lock-up expiry, Fell, analysts held, Large daily move, Weekly spike2026-04-17$1.6B$12.86-38.1%-29.3%7.5Buy (10)$25.44 +98%
GHRSGH Research PLCLeans up +3
weak
——2021-06-25$1.3B$18.56-36.3%+31.5%8.5Strong Buy (10)$42.89 +131%
MPLTMapLight Therapeutics, Inc.Leans up +3
medium
—Halved from offer2025-10-27$403M$6.42-35.5%-58.3%7.7Strong Buy (15)$26.54 +313%
KRMNKarman Holdings Inc.Up +4
strong
profitable 7.5%
revenue +36.6%
heavily indebted
Improving confidence2025-02-13$5.4B$32.99-34.2%+58.6%8.6Strong Buy (14)$67.00 +103%
ATTOAttovia Therapeutics, Inc.Leans up +2
weak
pre-revenue
revenue -100.0%
Shrinking revenue2026-08-05$691M$15.58-33.4%-12.3%8.0Strong Buy (5)$43.20 +177%
AKTSAktis Oncology, Inc.Up +4
strong
pre-revenue
revenue +336.9%
heavily indebted
—2026-01-09$927M$16.40-32.8%-14.8%9.5Strong Buy (10)$35.88 +119%
KARDKardigan, Inc.Leans up +3
weak
heavily indebted
—2026-06-18$1.3B$12.52-32.8%-20.9%9.4Strong Buy (9)$41.00 +227%
KGSKodiak Gas Services, Inc.Leans up +2
medium
profitable 11.3%
revenue +12.8%
heavily indebted
—2023-06-29$4.5B$42.69-32.4%+198.0%8.3Strong Buy (15)$72.64 +70%
WRDWeRide Inc.Leans up +2
medium
loss-making -199.0%
revenue +89.6%
heavily indebted
Halved from offer2024-10-25$1.4B$3.27-31.9%-74.4%7.7Strong Buy (13)$12.30 +277%
IMMXImmix Biopharma, Inc.Leans up +3
weak
——2021-12-16$657M$7.04-30.9%+41.2%7.9Strong Buy (7)$23.80 +238%
ALABAstera Labs, Inc.Up +4
medium
profitable 29.6%
revenue +115.1%
—2024-03-20$38.8B$211.60-30.7%+642.1%6.0Buy (25)$344.15 +63%
DSGNDesign Therapeutics, Inc.Leans up +3
weak
—Halved from offer2021-03-26$670M$9.32-30.7%—8.8Strong Buy (8)$21.57 +131%
AIPArteris, Inc.Leans up +3
weak
loss-making -44.8%
revenue +22.3%
heavily indebted
Improving confidence2021-10-27$962M$18.91-30.5%+38.5%10.0Strong Buy (7)$33.00 +75%
AMBQAmbiq Micro, Inc.Up +4
weak
loss-making -29.7%
revenue -4.7%
Improving confidence, Weekly spike2025-07-30$1.2B$45.60-30.1%+122.1%6.4Buy (7)$66.71 +46%
ARMArm Holdings plcLeans up +2
medium
profitable 17.1%
revenue +22.8%
heavily indebted
—2023-09-14$203.9B$177.17-29.8%+321.0%5.4Buy (43)$272.43 +54%
FIGRFigure Technology Solutions, Inc.Up +6
strong
profitable 33.7%
revenue +55.7%
heavily indebted
Improving confidence2025-09-11$5.7B$25.84-29.5%-3.3%6.5Buy (10)$47.20 +83%
BRVEBraveheart Bio, Inc.Leans up +3
weak
——2026-08-06$1.6B$19.27-29.1%+23.3%10.0Strong Buy (5)$45.50 +136%
SINDSinda Ltd.Leans up +3
weak
——2026-06-26$1.9B$11.18-29.1%-8.2%7.5Buy (6)$18.40 +65%
MNRMach Natural Resources LPLeans up +3
medium
profitable 20.7%
revenue +21.2%
liquidity 0.8
Fell on sound metrics, Profitable but deeply down, Thin liquidity, Halved from offer2023-10-25$1.5B$8.09-28.8%-45.3%7.8Strong Buy (9)$16.29 +101%
BROSDutch Bros Inc.Leans up +2
medium
profitable 5.1%
revenue +27.9%
heavily indebted
—2021-09-15$6.4B$34.15-28.8%+102.8%8.5Strong Buy (27)$55.04 +61%
KLRAKailera Therapeutics, Inc.Leans up +2
weak
—Lock-up expiry2026-04-17$1.7B$11.58-28.3%-22.3%9.3Strong Buy (7)$43.00 +271%
PICSPicS N.V.Up +5
strong
profitable 15.7%
revenue +65.0%
heavily indebted
Fell on sound metrics, Profitable but deeply down, Monthly spike, Halved from offer2026-01-29$962M$4.85-27.4%-61.3%8.9Strong Buy (9)$16.76 +246%
BKVBKV CorporationLeans up +3
medium
profitable 16.2%
revenue +41.6%
heavily indebted
—2024-09-26$2.1B$17.88-26.9%+22.4%9.6Strong Buy (11)$31.27 +75%
STUBStubHub Holdings, Inc.Up +4
strong
loss-making -91.3%
revenue -1.4%
heavily indebted
Fell, analysts held, Improving confidence, Halved from offer2025-09-17$2.0B$4.84-25.4%-77.8%5.4Buy (14)$9.21 +90%
TYRATyra Biosciences, Inc.Leans up +2
weak
——2021-09-15$1.4B$19.73-23.6%+26.2%8.7Strong Buy (15)$47.45 +140%
SKHYSK hynix Inc.Up +5
strong
profitable 85.6%
revenue +46.8%
heavily indebted
Improving confidence2026-07-10$663.0B$119.20-23.1%+2.6%7.7Strong Buy (15)$259.50 +118%
GENBGenerate Biomedicines, Inc.Up +4
strong
pre-revenue
revenue +55.9%
heavily indebted
—2026-02-27$1.6B$10.37-23.1%-23.7%8.0Strong Buy (5)$26.25 +153%
GFSGLOBALFOUNDRIES Inc.Leans up +3
weak
profitable 2.8%
revenue +0.6%
heavily indebted
Improving confidence2021-10-28$23.1B$38.94-22.4%-4.5%4.8Buy (23)$64.77 +66%
FIGFigma, Inc.Up +4
strong
loss-making -40.2%
revenue +41.0%
heavily indebted
Fell on sound metrics2025-07-31$10.4B$16.26-22.2%-30.4%2.8Buy (16)$27.41 +69%
HAWKHawkEye 360, Inc.Up +4
strong
loss-making -16.2%
revenue +162.6%
heavily indebted
Lock-up expiry, Fell on sound metrics, Improving confidence, Large daily move, Weekly spike, Monthly spike2026-05-07$1.8B$18.08-21.6%-35.5%8.6Strong Buy (11)$27.70 +53%
STDNStandard Nuclear, Inc.Leans up +2
weak
pre-revenue
Fell, analysts held2026-07-16$1.7B$9.01-20.7%-31.5%8.3Strong Buy (9)$16.88 +87%
ANLAdlai Nortye Group Ltd.Leans up +2
weak
heavily indebted
Fell, analysts held2023-09-29$683M$9.06-20.5%-58.0%10.0Strong Buy (7)$29.50 +226%
ETOReToro Group Ltd.Up +4
strong
profitable 2.4%
revenue +9.4%
heavily indebted
Fell on sound metrics, Profitable but deeply down, Halved from offer2025-05-14$1.8B$19.50-20.0%-57.5%6.0Buy (15)$36.60 +88%
MAIRMadison Air Solutions CorporationLeans up +3
medium
profitable 6.7%
revenue +34.1%
heavily indebted
Lock-up expiry, Improving confidence2026-04-16$14.1B$23.19-19.6%-11.1%8.5Strong Buy (10)$34.00 +47%
HOODRobinhood Markets, Inc.Leans up +3
medium
profitable 39.0%
revenue +51.6%
heavily indebted
Improving confidence2021-07-29$70.1B$68.65-19.1%+112.3%6.4Buy (32)$127.77 +86%
SSMRSunshine Silver Mining & Refining CompanyLeans up +3
medium
pre-revenue
revenue +421.8%
Lock-up expiry2026-06-04$1.9B$12.04-18.8%-19.7%6.7Buy (6)$19.08 +58%
RIVNRivian Automotive, Inc.Up +5
weak
loss-making -45.9%
revenue +8.4%
heavily indebted
Fell, analysts held, Upgrade, Improving confidence, Halved from offer2021-11-10$17.8B$11.29-18.1%-84.9%3.2Buy (25)$17.94 +59%
MBXMBX Biosciences, Inc.Up +4
weak
—Improving confidence2024-09-13$2.8B$53.41-18.0%+270.4%8.8Strong Buy (12)$95.09 +78%
CAVACAVA Group, Inc.Leans up +2
weak
profitable 4.5%
revenue +22.4%
heavily indebted
Improving confidence2023-06-15$6.8B$51.23-18.0%+177.7%6.1Buy (27)$75.42 +47%
CRCLCircle Internet Group, Inc.Leans up +3
medium
profitable 15.3%
revenue +63.9%
—2025-06-05$16.0B$51.88-16.6%+113.1%4.1Buy (29)$102.37 +97%
RLXRLX Technology Inc.Up +4
medium
profitable 21.9%
revenue +48.0%
Halved from offer2021-01-22$1.9B$1.46-16.6%—8.3Strong Buy (6)$2.78 +90%
QQnity Electronics, Inc.Leans up +2
medium
profitable 10.2%
revenue +9.7%
heavily indebted
—2025-10-27$24.7B$113.63-15.9%—8.5Strong Buy (10)$173.30 +53%
VORVor Biopharma Inc.Leans up +3
weak
—Halved from offer2021-02-05$1.2B$18.52-15.6%—8.5Strong Buy (10)$39.00 +111%
IPSCCentury Therapeutics, Inc.Leans up +3
medium
revenue +1556.8%
heavily indebted
Halved from offer2021-06-17$300M$1.32-15.4%—7.0Buy (5)$4.75 +260%
AUNAAuna S.A.Up +4
strong
profitable 0.3%
revenue -0.0%
heavily indebted
Fell on sound metrics, Profitable but deeply down, Halved from offer2024-03-22$340M$3.90-14.7%-63.2%6.4Buy (7)$6.99 +79%
BLSMBlossomHill Therapeutics, Inc.Leans up +3
weak
——2026-08-07$446M$14.41-14.4%-19.4%9.0Strong Buy (5)$35.40 +146%
RELYRemitly Global, Inc.Up +5
strong
profitable 19.1%
revenue +29.4%
heavily indebted
Fell on sound metrics, Profitable but deeply down, Halved from offer2021-09-23$4.8B$20.06-14.3%-40.5%9.0Strong Buy (10)$32.00 +60%
WBIWaterBridge Infrastructure LLCLeans up +3
medium
profitable 1.2%
revenue +66.2%
heavily indebted
Improving confidence2025-09-17$3.4B$24.99-13.6%+55.5%5.6Buy (8)$36.75 +47%
TCBXThird Coast Bancshares, Inc.Leans up +3
medium
profitable 30.7%
revenue +21.9%
heavily indebted
Improving confidence2021-11-09$661M$37.60-13.3%+66.4%4.3Buy (7)$47.36 +26%
CINTCI&T Inc.Leans up +2
medium
profitable 6.8%
revenue +11.6%
heavily indebted
Profitable but deeply down, Halved from offer2021-11-10$390M$2.87-13.3%-79.5%6.5Buy (10)$5.63 +96%
DCDakota Gold Corp.Leans up +3
weak
——2022-04-05$715M$4.36-13.1%—9.2Strong Buy (6)$12.26 +181%
AFRMAffirm Holdings, Inc.Leans up +3
medium
profitable 43.9%
revenue +32.1%
heavily indebted
—2021-01-13$22.1B$56.91-12.6%—7.2Buy (36)$95.81 +68%
JCAPJefferson Capital, Inc.Leans up +2
medium
profitable 23.5%
revenue +41.5%
heavily indebted
Large daily move2025-06-26$1.2B$20.94-11.7%+42.4%7.0Buy (5)$28.60 +37%
VIKViking Holdings LtdLeans up +3
medium
profitable 19.3%
revenue +21.9%
liquidity 0.8
heavily indebted
Thin liquidity, Upgrade, Improving confidence2024-05-01$40.1B$95.00-10.0%+272.6%8.9Strong Buy (23)$110.05 +16%
INBXInhibrx Biosciences, Inc.Leans up +3
weak
revenue +550.0%
Improving confidence2024-05-28$1.2B$74.33-9.5%—7.5Buy (4)$266.67 +259%
AVAHAveanna Healthcare Holdings Inc.Leans up +3
medium
profitable 11.4%
revenue +20.2%
heavily indebted
Improving confidence2021-04-29$2.5B$10.70-9.4%—6.4Buy (11)$15.20 +42%
KSPIJoint Stock Company Kaspi.kzLeans up +2
medium
profitable 24.3%
revenue +59.8%
heavily indebted
—2024-01-19$17.1B$85.80-9.2%-0.5%5.7Buy (7)$106.52 +24%
ZBIOZenas BioPharma, Inc.Leans up +3
medium
pre-revenue
revenue +100.0%
—2024-09-13$1.9B$25.04-8.2%+61.0%8.8Strong Buy (8)$47.88 +91%
ASAmer Sports, Inc.Leans up +2
medium
profitable 7.3%
revenue +26.7%
heavily indebted
—2024-02-01$17.4B$29.51-8.1%+124.5%8.5Strong Buy (27)$47.47 +61%
LBLandBridge CorporationLeans up +2
medium
profitable 17.1%
revenue +81.1%
heavily indebted
—2024-06-28$5.6B$71.43-8.0%+424.8%4.3Buy (7)$89.57 +25%
AURAAura Biosciences, Inc.Leans up +2
weak
heavily indebted
Fell, analysts held2021-10-29$740M$6.98-7.4%-53.3%9.2Strong Buy (6)$16.60 +138%
FLYFirefly Aerospace Inc.Leans up +3
medium
loss-making -88.4%
revenue +162.9%
heavily indebted
Fell on sound metrics, Weekly spike, Monthly spike, Halved from offer2025-08-07$4.3B$19.52-7.2%-56.0%5.9Buy (11)$36.64 +88%
TPGTPG Inc.Leans up +2
medium
profitable 7.5%
revenue +27.0%
heavily indebted
—2022-01-13$18.6B$45.59-6.8%+69.5%5.9Buy (17)$59.53 +31%
VINPVinci Compass Investments Ltd.Leans up +3
medium
profitable 25.7%
revenue +62.7%
heavily indebted
Halved from offer2021-01-28$577M$8.22-6.7%—7.5Buy (6)$12.63 +54%
BBNXBeta Bionics, Inc.Leans up +3
medium
loss-making -65.3%
revenue +53.9%
—2025-01-30$893M$13.32-6.5%-2.2%6.7Buy (15)$25.10 +88%
PHVSPharvaris N.V.Leans up +3
weak
——2021-02-05$2.3B$31.66-5.5%—8.9Strong Buy (14)$58.16 +84%
FSBCFive Star BancorpLeans up +2
medium
profitable 41.3%
revenue +25.7%
heavily indebted
—2021-05-05$1.1B$41.87-5.4%—5.0Buy (5)$51.40 +23%
LIFEEthos Technologies Inc.Leans up +2
medium
loss-making -16.2%
revenue +52.0%
—2026-01-29$2.2B$32.13-5.4%+122.7%7.8Strong Buy (9)$53.38 +66%
SPCXSpace Exploration Technologies Corp.Up +4
strong
loss-making -8.6%
revenue +33.2%
heavily indebted
Improving confidence2026-06-12$1.89T$138.43-4.9%+4.7%6.5Buy (40)$255.63 +85%
VGVenture Global, Inc.Leans up +3
medium
profitable 31.1%
revenue +176.9%
liquidity 0.9
heavily indebted
Profitable but deeply down, Thin liquidity, Improving confidence2025-01-24$33.1B$12.13-4.4%-41.3%5.0Buy (17)$17.56 +45%
PAYPPayPay CorporationUp +5
strong
profitable 16.3%
revenue +25.9%
heavily indebted
—2026-03-12$9.7B$12.91-4.1%-13.1%7.7Strong Buy (13)$23.67 +83%
NXTNextpower Inc.Up +4
medium
profitable 16.0%
revenue +20.3%
Improving confidence2023-02-09$14.3B$75.95-4.1%+244.0%7.7Strong Buy (30)$127.90 +68%
SGMTSagimet Biosciences Inc.Leans up +2
weak
——2023-07-14$729M$9.62-2.0%-37.2%7.5Buy (12)$27.27 +183%
FRBTForbright, Inc.Leans up +3
medium
profitable 13.7%
revenue +30.2%
heavily indebted
—2026-06-11$951M$17.11-1.9%+2.5%6.7Buy (6)$23.25 +36%
YMMFull Truck Alliance Co. Ltd.Up +6
strong
profitable 33.0%
revenue +11.1%
Fell on sound metrics, Profitable but deeply down, Halved from offer2021-06-22$9.0B$9.06-1.7%-56.5%7.3Buy (15)$12.51 +38%
DLODLocal LimitedUp +5
medium
profitable 15.0%
revenue +46.6%
Improving confidence, Halved from offer2021-06-03$3.9B$12.67-1.6%—7.5Buy (10)$18.50 +46%
PTRNPattern Group Inc.Leans up +3
medium
profitable 3.6%
revenue +39.3%
heavily indebted
Upgrade2025-09-19$3.6B$18.86-1.4%+32.4%8.9Strong Buy (9)$27.88 +48%

Showing 94 of 470 tracked IPOs. Our balance, the flags, the fundamentals and the analyst figures come from the weekly run of 2026-11-16. Prices are refreshed daily and were last taken on 2026-11-19; a thinly traded company shows its most recent trade, which may be older. Use the filters to narrow the list, or click a column heading to sort.

The three-month window is deliberate. A week is noise and a year buries the move in the IPO itself; three months is long enough for a repricing and short enough that the published views have had time to react and have not. Where a company carries a Lock-up expiry flag, part of the fall may be supply rather than sentiment — the dates are on the Key Dates page, with how many normal trading sessions the unlocking stock would take to absorb.

How to read this. Our score runs from −10 to +10 and is computed here from the filings and the price history, not copied from anyone — the Scores page sets out what goes into it and Method says where every figure comes from. Our view is the direction that score leans, in words. Consensus is the analyst consensus with the number of analysts behind it in brackets; a consensus resting on four or five people is not the same object as one resting on thirty, which is why the count is always shown. Implied upside is the consensus target against the latest close. The 3-month change is highlighted where the move is 40% or more in either direction. Of the 470 listed IPOs we track, 105 are left out of both screens before anything is ranked: 9 are under a takeover offer, 32 carry no consensus target at all, 36 are followed by fewer than four analysts, 7 trade below a dollar, and 21 show an implied upside above 300%, counting each by the first test it fails. Two of those deserve a word. A target three times the share price is almost always a target nobody has revised, not a bullish call. And a company under a takeover offer is not a disagreement at all: the price tracks the bid and the rating goes to hold, which is the mechanism working, not a gap between the market and the page. A disagreement is not a forecast and not a recommendation: it says the price and the published view have moved apart, and gives you the pieces to work out which one you find more convincing. Nothing on this page is a recommendation to buy or sell.